NCT05649137: An ongoing trial by Novo Nordisk A/S
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05649137 |
|---|---|
| Title | Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 4, 2023 |
| Completion date | Oct. 28, 2024 |
| Required reporting date | Oct. 28, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |